InvestSmart
-
Cramer’s Right on Marvell — and Way Too Casual on Bausch’s Risk
When Jim Cramer says “buy,” Wall Street listens. Retail traders sprint. And somewhere, a hedge fund quietly takes the other side. Now he’s bullish on Marvell (MRVL) and Bausch Health (BHC). Two very different beasts — one riding the AI semiconductor wave, the other dragging around a pharmaceutical debt hangover. So the question isn’t whether…
-
Marvell Is a Real AI Bet. Bausch Is a Hope Trade.
Jim Cramer is pounding the table on Marvell and Bausch. That’s usually when retail investors start chasing. The question isn’t whether these stocks have momentum. They do. The question is whether you’re buying a real earnings inflection — or just volunteering to be the exit liquidity. Here’s the blunt answer: Marvell looks like a breakout…
-
Stop Treating Marvell and Bausch Like the Same Trade
Follow or Fade? Trading Marvell and Bausch After Cramer’s Buy Calls When Jim Cramer pounds the table, do you grab a seat—or head for the exit? That’s the question with Marvell (MRVL) and Bausch Health (BHC). One is riding the AI chip wave with real numbers to back it up. The other is grinding through…
-
Stop Trading Like the Fed Is Your Safety Net
You must be logged in to post a comment.